Itrawall 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itrawall 100 is indicated for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. It is effective against a wide range of pathogenic fungi, including Candida species, Aspergillus species, and dermatophytes. The capsule formulation ensures adequate bioavailability and convenient oral administration. Dosage and duration of therapy should be tailored to the specific infection and patient response, with careful consideration of hepatic function and potential drug interactions due to itraconazole’s metabolism via the cytochrome P450 system. Common adverse effects include gastrointestinal disturbances, headache, and rash, while serious adverse reactions may involve hepatotoxicity and cardiac effects. Itrawall 100 should be used under medical supervision with appropriate monitoring to ensure efficacy and safety.